Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin

S P Kraft, A E Lang, S P Kraft, A E Lang

Abstract

Blepharospasm, the most frequent feature of cranial dystonia, and hemifacial spasm are two involuntary movement disorders that affect facial muscles. The cause of blepharospasm and other forms of cranial dystonia is not known. Hemifacial spasm is usually due to compression of the seventh cranial nerve at its exit from the brain stem. Cranial dystonia may result in severe disability. Hemifacial spasm tends to be much less disabling but may cause considerable distress and embarrassment. Patients affected with these disorders are often mistakenly considered to have psychiatric problems. Although the two disorders are quite distinct pathophysiologically, therapy with botulinum toxin has proven very effective in both. We review the clinical features, proposed pathophysiologic features, differential diagnosis and treatment, including the use of botulinum toxin, of cranial dystonia and hemifacial spasm.

References

    1. Trans Am Acad Ophthalmol Otolaryngol. 1967 Jul-Aug;71(4):656-64
    1. Am J Ophthalmol. 1968 Jun;65(6):889-90
    1. Arch Neurol. 1971 Jul;25(1):81-7
    1. Geriatrics. 1972 Aug;27(8):69-73
    1. Adv Neurol. 1976;14:245-58
    1. Science. 1976 Sep 24;193(4259):1256-8
    1. J Neurol Neurosurg Psychiatry. 1976 Dec;39(12):1204-9
    1. J Neurosurg. 1977 Sep;47(3):321-8
    1. J Neurol Neurosurg Psychiatry. 1978 Apr;41(4):361-5
    1. Can Med Assoc J. 1978 Jul 8;119(1):48-9
    1. Neurology. 1979 Aug;29(8):1126-30
    1. Neurology. 1979 Sep;29(9 Pt 1):1261-72
    1. Neurology. 1980 Jul;30(7 Pt 1):690-5
    1. Ann Neurol. 1981 Feb;9(2):189-91
    1. Laryngoscope. 1983 Jan;93(1):9-16
    1. Ann Neurol. 1983 Apr;13(4):402-11
    1. Am J Otol. 1983 Apr;4(4):350-1
    1. Neurology. 1983 Aug;33(8):1100-2
    1. Neurology. 1983 Sep;33(9):1237-40
    1. Arch Ophthalmol. 1984 Feb;102(2):266-8
    1. Arch Ophthalmol. 1984 Feb;102(2):269-73
    1. Neurology. 1984 Apr;34(4):418-26
    1. Ann Ophthalmol. 1984 Apr;16(4):371-6
    1. Am J Ophthalmol. 1984 Jul 15;98(1):28-31
    1. Neurology. 1985 Jan;35(1):138
    1. Arch Ophthalmol. 1985 Mar;103(3):347-50
    1. Neurology. 1985 May;35(5):766-9
    1. Am J Ophthalmol. 1985 May 15;99(5):542-6
    1. Am J Ophthalmol. 1985 Aug 15;100(2):305-7
    1. Arch Ophthalmol. 1985 Sep;103(9):1305-6
    1. Brain. 1985 Sep;108 ( Pt 3):593-608
    1. Can J Neurol Sci. 1985 Nov;12(4):314-6
    1. Am J Ophthalmol. 1986 Feb 15;101(2):232-5
    1. Can J Neurol Sci. 1986 Feb;13(1):42-6
    1. Arch Neurol. 1986 Sep;43(9):866-8
    1. Can J Ophthalmol. 1986 Aug;21(5):167-9
    1. Neurology. 1987 Jan;37(1):123-8
    1. Ophthalmology. 1986 Dec;93(12):1621-7
    1. Can J Ophthalmol. 1987 Feb;22(1):24-8
    1. Neurology. 1987 Apr;37(4):616-23
    1. Mov Disord. 1986;1(1):51-8
    1. J Neurol Neurosurg Psychiatry. 1983 May;46(5):465-6
    1. Neurology. 1963 Jan;13:77-8
    1. Arch Pathol. 1963 Jul;76:55-9
    1. Arch Ophthalmol. 1981 Jun;99(6):1056-62
    1. Pharmacol Rev. 1981 Sep;33(3):155-88
    1. Neurology. 1982 Mar;32(3):286-7
    1. Trans Am Ophthalmol Soc. 1981;79:734-70
    1. JAMA. 1982 Jun 18;247(23):3244-5
    1. Can J Neurol Sci. 1982 Aug;9(3):313-9
    1. J Clin Psychopharmacol. 1982 Oct;2(5):321-8
    1. J Neurosurg. 1982 Dec;57(6):753-6
    1. JAMA. 1982 Dec 17;248(23):3160-4

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren